Thanks to flailing pharma revenues and its decision to ship away its oncology assets, GlaxoSmithKline has a lot riding on vaccines. And in 2015, the unit delivered with 19% revenue growth, although profit and operating margin both fell.
GlaxoSmithKline CEO Andrew Witty is running out of ways to say it: A spinoff of the consumer health joint venture it shares with Novartis just isn't happening right now.
All 69 of the United States' National Cancer Institute-designated centers have joined together to issue a statement urging an increase in HPV vaccinations, declaring the vaccines "tragically underused" and calling low uptake a "public health threat."
As the global alarm continues to sound about the Zika virus, Sanofi said on Tuesday that it's getting involved. In doing so, it became the first major pharmaceutical company to get involved in the Zika vaccine race, launching a program to develop a jab just after receiving the first regulatory approvals for its dengue shot.
Last year, GlaxoSmithKline traded away most of its cancer assets to Novartis in exchange for the majority of the Swiss drugmaker's vaccines portfolio. But it's not out of the area altogether, and now, it's sweetening a deal with oncology partner Adaptimmune.
GlaxoSmithKline, working with Adaptimmune on therapies that use the body's machinery to fight cancer, is sweetening the deal for its partner, promising more cash to accelerate development of a promising treatment for soft tissue sarcoma.
The biotech team at Index Ventures is splitting away to focus exclusively on what they do best: jump-starting new therapeutic programs in Europe.
A clutch of big-name drugmakers have teamed up to digitize the drug formulation development process. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer are involved with the initiative, which is aiming to develop digital tools and processes that spot nonviable molecules earlier in development.
GlaxoSmithKline has been experiencing a high demand for its meningitis B vaccine Bexsero that has led to a shortage of doses for U.K. private clinics outside of the country's National Health Service.
Science Insider has cautioned that a federal indictment against Yu Xue and Lucy Xi and three associates for allegedly stealing trade secrets from GlaxoSmithKline in the U.S. related to work on an anti-HER3 antibody may test prosecutors' ability to get a conviction.